| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Varenicline, a drug for smoking cessation, increases the risk of cardiovascular event. Chronic obstructive pulmonary disease (COPD) is characterized by pulmonary inflammation and emphysema. In COPD patients, smoking cessation is one of the most effective treatments. However, it is unclear whether varenicline increases the risk of cardiovascular event under COPD conditions. In this study, to clarify the adverse effect of varenicline under COPD conditions, apolipoprotein E knockout (ApoE KO) mice were administrated porcine pancreatic elastase (PPE) to induce emphysema.
Varenicline promoted the atherosclerosis in ApoE KO mice, while it didn’t aggravate the atherosclerosis in PPE-treated ApoE KO mice. Interestingly, varenicline blocked the PPE-induced alveolar enlargement. In summary, varenicline may increase the risk of cardiovascular event and protect PPE-induced emphysema. Thus, the protective effect of varenicline against COPD may not promote the atherosclerosis under COPD conditions.
|
